Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms

The impact of a biomarker-based (personalized) cancer treatment strategy in the setting of phase 1 clinical trials was analyzed.To compare patient outcomes in phase 1 studies that used a biomarker selection strategy with those that did not.PubMed search of phase 1 cancer drug trials (January 1, 2011, through December 31, 2013).Studies included trials that evaluated single agents, and reported efficacy end points (at least response rate...